Drug intelligence / Profile preview

somatropin (HL-032 oral tablet biobetter)

Development stage: Phase 1
Lead developer: HanAll BioPharma
Modality: Small Molecules
Administration: Oral

Overview

HL-032 is an **oral biobetter tablet formulation of human growth hormone (somatropin)** developed by HanAll Biopharma, originally from Nautilus Biotech. It acts as an agonist of the somatotropin receptor, mimicking endogenous human growth hormone to stimulate growth and metabolism. HL-032 was designed to address somatropin deficiency but development has been discontinued after Phase I trials in healthy volunteers in South Korea. The formulation aims to improve administration convenience compared to injectable recombinant hGH[5][7][1].

Brand names: HanTropinResist-hGHVitatropin
Other names: HL 032HL032HL-032Oral hGH - HanAll BiopharmahGH - HanAll Biopharma

Targets

GHR (Growth hormone receptor)

Beyond the preview

Go deeper on somatropin (HL-032 oral tablet biobetter).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on somatropin (HL-032 oral tablet biobetter).

Explore the full profile